Rallybio’s Promising Pipeline and Clinical Milestones Earns Buy Rating from Analyst Jonathan Wolleben
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Rallybio (RLYB – Research Report) today and set a price target of ...